目的 探讨妇科止带胶囊联合甲硝唑片治疗慢性盆腔炎的临床疗效。方法 选取2015年3月—2016年7月辽阳市中心医院接收的慢性盆腔炎患者120例为研究对象，所有患者随机分为对照组和治疗组，每组各60例。对照组口服甲硝唑片，0.4 g/次，2次/d。治疗组在对照组基础上口服妇科止带胶囊，4粒/次，3次/d。两组患者均连续治疗14 d。观察两组的临床疗效，比较两组的血清细胞因子水平和临床症状评分。结果 治疗后，对照组和治疗组的总有效率分别为81.67%、93.33%，两组比较差异有统计学意义（P < 0.05）。治疗后，两组白细胞介素-4（IL-4）水平明显升高，肿瘤坏死因子-α（TNF-α）、超敏反应C蛋白（hs-CRP）水平明显降低，同组治疗前后比较差异具有统计学意义（P < 0.05）；且治疗组这些观察指标的改善程度明显优于对照组，两组比较差异具有统计学意义（P < 0.05）。治疗后，两组临床症状评分均显著降低，同组治疗前后比较差异有统计学意义（P < 0.05）；且治疗组临床症状评分明显低于对照组，两组比较差异具有统计学意义（P < 0.05）。结论 妇科止带胶囊联合甲硝唑片治疗慢性盆腔炎具有较好的临床疗效，能改善临床症状，调节血清细胞因子水平，安全性较好，具有一定临床推广应用价值。

Objective To investigate the clinical efficacy of Fukezhidai Capsules combined with Metronidazole Tablets in treatment of chronic pelvic inflammatory disease. Methods Women (120 cases) with chronic pelvic inflammatory disease in Liaoyang City Central Hospital from March 2015 to July 2016 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Metronidazole Tablets, 0.4 g/time, twice daily. Patients in the treatment group were po administered with Fuke Zhidai Capsules on the basis of the control group, 4 capsules/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the clinical symptom scores and inflammatory factor levels before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.67% and 93.33%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of IL-4 in two groups were significantly increased, but the levels of TNF-α and hs-CRP in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, clinical symptom scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And clinical symptom scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Fukezhidai Capsules combined with Metronidazole Tablets has clinical curative effect in treatment of chronic pelvic inflammatory disease, can improve the clinical symptoms and regulate the level of serum cytokine with better safety, which has a certain clinical application value.